Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Parallel Group, Randomised, Placebo Controlled, Double Blind Oral Assessment of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

The purpose of the study is to investigate the clinical effects of multiple (28 day) twice-daily doses of OC000459 in comparison to placebo on clinic lung function (FEV1) in mild to moderate asthmatics with an FEV1 of 60-80% of predicted and requiring only short acting inhaled B2-adrenergic agonists for symptomatic control.

Inclusion Criteria At Screening:

• Male or female asthmatics, any racial group. Females of childbearing potential must practise two forms of contraception
• Non smokers
• Mild to moderate asthmatics according to GINA guidelines for at least 12 months.
• History of asthma symptoms increasing in response to external allergens.
• Testing positive on skin prick test to an allergen associated with the subject's asthma

Exclusion Criteria:

• Use of inhaled or local corticosteroids in the period from 28 days prior to screening.
• Receipt of prescribed or over the counter medication within 14 days of the first study day.